Use of Ovatodiolide against SARS-CoV-2
US12403125B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 17, 2020 |
| Grant date | Sep 2, 2025 |
| Priority date | — |
| Expiry date | Nov 7, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/39
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of Formula I compound—Ovatodiolide which is safe and effective to use in a pharmaceutical composition for inhibition of SARS-CoV-2 is provided. The pharmaceutical composition comprising a safe and effective amount of a compound of Formula I compound—Ovatodiolide or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, which has great potential to treat SARS-CoV-2 induced COVID-19 based on a safe and effective amount of a compound of Formula I compound—Ovatodiolide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.